Merck Announces Third-Quarter 2021 Financial Results
Results Demonstrate Strong Momentum Across Business Third-Quarter 2021 Worldwide Sales Were $13.2 Billion, 20% Above Third-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Grew 19% Reflecting Strong Demand for the Company’s Robust Portfolio: KEYTRUDA Sales Grew 22% to $4.5 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 21% GARDASIL/GARDASIL 9 Sales Grew 68% to $2.0 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 63% Animal Health Sales Grew 16% to $1.4 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 14% Third-Quarter 2021 GAAP EPS from Continuing Operations Was $1.80; Third-Quarter 2021 Non-GAAP EPS from Continuing Operations Was $1.75 Bolstered Innovation with Agreement to Acquire Acceleron Pharma, Complementing and Expanding Merck’s Cardiovascular Pipeline Progressed Regulatory Applications, Secured Multiple Regulatory Approvals, and Saw Advancement of Key Government Recommendations, Including: Submission of Emergency
https://www.merck.com/news/merck-announces-third-quarter-2021-financial-results/
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in Stage II Melanoma (KEYNOTE-716) and Recurrent, Persistent or Metastatic Cervical Cancer (KEYNOTE-826) Selected for ESMO Presidential Symposium Sessions and Official Press Program New Data for KEYTRUDA Demonstrate Significant Progress in Breast and Gynecological Cancer Clinical Programs Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data spanning 20 types of cancer from its leading oncology research program will be presented at the European Society for Medical Oncology (ESMO) Congress 2021 from Sept. 16–21. Key data include new Phase 3 results for the company’s oncology medicines, specifically: KEYTRUDA, Merck’s anti-PD-1 therapy in melanoma (KEYNOTE-716) and recurrent, persistent or metastatic cervical cancer (KEYNOTE-826), which were selected for inclusion in the ESMO Presidential Symposium sessions and the ESMO Press Program, and in metastatic triple-negative breast cancer (TNBC)
https://www.merck.com/news/merck-to-present-new-data-from-its-broad-oncology-portfolio-and-pipeline-at-esmo-2021-including-in-earlier-stages-of-cancer/
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
First-Time Data for KEYTRUDA® (pembrolizumab) in Early-Stage Kidney Cancer and for LYNPARZA® (olaparib) in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8. These data include new or updated findings from Merck’s broad oncology portfolio and diverse pipeline including KEYTRUDA, Merck’s anti-PD-1 therapy; LYNPARZA (in collaboration with AstraZeneca); LENVIMA ® (lenvatinib, in collaboration with Eisai); and belzutifan, an investigational hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. “Our expansive oncology clinical development program is designed to help us understand the full potential of our established and pipeline medicines and
https://www.merck.com/news/merck-highlights-scientific-data-at-2021-asco-annual-meeting-across-more-than-20-cancer-types-from-broad-oncology-research-program/
Merck Announces First-Quarter 2021 Financial Results
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 Entered into HIV Collaboration with Gilead Sciences, Inc. and Completed Acquisition of Pandion Therapeutics, Inc. Merck Will Host an Investor Event Featuring Organon on May 3; Organon Spinoff is Expected to be Completed on June 2, with First Day of Trading Scheduled for June 3 2021 Financial Outlook Continues to Expect Sales Growth of 8% to 12%; Full-Year 2021 Sales Estimated to be Between $51.8 Billion and $53.8 Billion, Including a Positive Impact from Foreign Exchange of Less Than 2%, Assuming Organon is Part of Merck for the Full Year Expects Full-Year 2021 GAAP EPS to
https://www.merck.com/news/merck-announces-first-quarter-2021-financial-results/